No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract ENESTnd: Frontline nilotinib therapy shows improvement in long-term efficacy outcomes for patients in the chronic phase of newly diagnosed chronic myeloid leukemia

byKathleen Lau

February 4, 2021

in StudyGraphics

Hypertension and obesity associated with changes in retinal microvasculature for children

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is noninferior to intravenous administration in HER2⁺ breast cancer

#VisualAbstract: Incidence and prevalence of melanomas and keratinocyte carcinomas have increased from 1990 to 2017

Non-TNF-targeted therapies more effective than anti-TNF agents in uncontrolled rheumatoid arthritis

Tocilizumab is superior to rituximab for treatment of rheumatoid arthritis in patients with low or absent B-cell lineage expression

$Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma$

Phase II O-12-M1: Melflufen plus dexamethasone showed benefits in long-term survival outcomes in relapsed/refractory multiple myeloma

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports